Categories: Health

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

 | Source: Vera Therapeutics

BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option granted on June 3, 2025 has an exercise price per share equal to $30.91, Vera’s closing trading price on June 3, 2025. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of August 20, 2025, subject to the new employee’s continued service relationship with Vera through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. For more information, please visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com

GlobeNews Wire

Recent Posts

Medidata Secures a Leader Position in Everest Group’s PEAK Matrix Assessment for eCOA, Driving the New Patient Experience Forward

Medidata eCOA was the highest Leader recognized in the evaluation, supporting over 1M+ patients and…

24 minutes ago

SEMI Reports Global Semiconductor Equipment Billings Increased 24% Year-Over-Year in Q2 2025

Strong Growth in the First Half of the Year Driven by Advanced Logic and DRAM…

24 minutes ago

Salesforce Announces Quarterly Dividend

SAN FRANCISCO--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world’s #1 AI CRM, today announced that its board…

1 hour ago

Deok-ho Lim of NEL Animal Cardiovascular Center Delivers Keynote Speech at Jiangsu Province Pet Economic Development Conference

HUAIAN, China--(BUSINESS WIRE)--#2ndJiangsuProvincePetEconomicDevelopmentConference--Deok-ho Lim, director at SV Cross-border Group, a company specializing in the international…

1 hour ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

September 04, 2025 20:00 ET  | Source: HUTCHMED (China) Limited HONG KONG and SHANGHAI and…

3 hours ago

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a…

3 hours ago